NDA 021992 · Pf Prism Cv
Pristiq
Desvenlafaxine Succinate · Oral
NovelLast checked: Nov 19, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Feb 29, 2008
Approved uses
3
Original approval plus efficacy supplements
Registered trials
89
37 Phase 3, 4 recruiting
FAERS reports
23,629
9,187 serious, 458 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions (5.1) ] . In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions (5.1) ] . PRISTIQ is not approved for use in pediatric patients [see Use in Specific Populations (8.4) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information...
What it is approved for
From the label in effect Apr 28, 2026.
PRISTIQ is indicated for the treatment of adults with major depressive disorder (MDD) [see Clinical Studies (14) ] . PRISTIQ is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of adults with major depressive disorder (MDD) ( 1 ).
Mechanism: The exact mechanism of the antidepressant action of desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective SNRI.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 6, 2018 Supplement 42 · Efficacy LabelLetterPediatric Medical Review
- Feb 14, 2013 Supplement 33 · Efficacy LetterLabel
- Feb 29, 2008 Original approval · Type 1 - New Molecular Entity NovelLabelReviewLetter
3 products under this application
- PRISTIQ · DESVENLAFAXINE SUCCINATE EQ 100MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- PRISTIQ · DESVENLAFAXINE SUCCINATE EQ 25MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- PRISTIQ · DESVENLAFAXINE SUCCINATE EQ 50MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Desvenlafaxine" as an intervention, any sponsor and status, largest first.
- Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal WomenPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00683800 · 2,186 participants · Start Jun 2008 · Primary completion May 2010
Drug: desvenlafaxine succinate (DVS) SR; Placebo · For: Vasomotor Symptoms
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 121 sites in all
- Long-Term Safety Of DVS-233 SR In Patients With Major Depressive DisorderPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01309542 · 1,403 participants · Start Aug 2003 · Primary completion Mar 2006
Drug: Desvenlafaxine Succinate · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Mesa, Arizona; Peoria, Arizona · 117 sites in all
- Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)Pivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01715805 · 1,022 participants · Start Nov 15, 2012 · Primary completion Jun 24, 2016
Drug: Cariprazine; Placebo and 1 more · For: Major Depressive Disorder
Sites: Tucson, Arizona; Little Rock, Arkansas; Cerritos, California · 85 sites in all
- Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01432457 · 924 participants · Start Oct 2011 · Primary completion Jul 2012
Drug: desvenlafaxine succinate sustained-release 50 mg/day; desvenlafaxine succinate sustained-release 100 mg/day and 1 more · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Little Rock, Arkansas; Arcadia, California · 61 sites in all
- Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive DisorderPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00887224 · 874 participants · Start Jun 2009 · Primary completion Mar 2011
Drug: Desvenlafaxine succinate sustained release 50 mg; Desvenlafaxine succinate sustained release 25 mg and 1 more · For: Major Depressive Disorder
Sites: Beverly Hills, California; Encino, California; Los Alamitos, California · 90 sites in all
- Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00797966 · 850 participants · Start May 2009 · Primary completion Jun 2010
Drug: OPC-34712; Placebo and 1 more · For: Major Depressive Disorder
Sites: Arcadia, California; Beverly Hills, California; Escondido, California · 50 sites in all
- Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive DisorderPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01469377 · 819 participants · Start Dec 15, 2011 · Primary completion Dec 12, 2013
Drug: Placebo; Cariprazine · For: Major Depressive Disorder
Sites: Garden Grove, California; National City, California; Oceanside, California · 72 sites in all
- Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDDPivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00445679 · 807 participants · Start Jul 2007 · Primary completion Feb 2009
Drug: DVS SR; Paroxetine · For: Depressive Disorder, Major
Sites: Beijing, China; Guangdong Province, China; Hunan Province, China · 43 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective2,459
- nausea2,241
- headache1,794
- dizziness1,765
- anxiety1,654
- fatigue1,517
- insomnia1,466
- feeling abnormal1,383
- depression1,238
- drug withdrawal syndrome1,012
- malaise972
- diarrhoea862
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1,213 |
| 2009 | 495 |
| 2010 | 4,881 |
| 2011 | 2,010 |
| 2012 | 2,244 |
| 2013 | 1,800 |
| 2014 | 717 |
| 2015 | 143 |
| 2016 | 1,718 |
| 2017 | 1,313 |
| 2018 | 903 |
| 2019 | 1,054 |
| 2020 | 918 |
| 2021 | 434 |
| 2022 | 1,034 |
| 2023 | 825 |
| 2024 | 701 |
| 2025 | 757 |
| 2026 | 469 |
Recalls
1 FDA enforcement reports for this application.
Apr 16, 2014 · Class II · Terminated
Presence of Foreign Tablets/Capsules: Pfizer is recalling 50 mg Pristiq (desvenlafaxine) extended release tablets because a single Pristiq 100 mg tablet was found in a bottle of 50 mg Pristiq.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Pristiq (Desvenlafaxine Succinate)
2024 spending
$6.1M
Beneficiaries
1,470
7,562 claims
Per beneficiary
$4,121
$13.98 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $10,668,530 |
| 2021 | $9,380,716 |
| 2022 | $7,767,776 |
| 2023 | $6,611,882 |
| 2024 | $6,057,588 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis.
Pillinger T, Arumuham A, McCutcheon RA, et al. · Lancet 2025 · Network Meta-Analysis, Systematic Review
- Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, et al. · Mol Psychiatry 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis.
Henssler J, Schmidt Y, Schmidt U, et al. · Lancet Psychiatry 2024 · Systematic Review, Meta-Analysis
- New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE, McKenzie JE, Bailey AP, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis.
Zhou X, Teng T, Zhang Y, et al. · Lancet Psychiatry 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.
Morga A, Ajmera M, Gao E, et al. · Menopause 2024 · Systematic Review, Network Meta-Analysis
Sponsor: Pf Prism Cv
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.